Penny Heaton, M.D., Global Therapeutic Area Head, Vaccines, Janssen Research & Development, LLC
NEW BRUNSWICK, N.J., December 16, 2021 - Remarks made by Penny Heaton, Global R&D Head of Vaccines, Janssen Pharmaceutical Companies of Johnson & Johnson:Good afternoon. My name is Penny Heaton, and I am the Global R&D Head for Vaccines at Janssen.Let me state at the outset that based on data, we are confident in the positive benefit-risk profile of our vaccine. It is saving lives here in the US today and on every continent around the globe. Our vaccine is different. It is long-lasting, it offers high levels of protection, and it provides breadth of protection. Our vaccine has flexible dosing, is easy to store ...
Source: Johnson and Johnson - December 16, 2021 Category: Pharmaceuticals Source Type: news
FDA Updates TTS Risks, Cautions for Janssen COVID-19 Vaccine FDA Updates TTS Risks, Cautions for Janssen COVID-19 Vaccine
The vaccine ' s updated fact sheets include a contraindication for a subgroup of potential recipients as well as mortality figures for people who develop thrombosis with thrombocytopenia syndrome.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - December 15, 2021 Category: Cardiology Tags: Cardiology News Source Type: news
Class I Recall of Percutaneous Thrombolytic Device Class I Recall of Percutaneous Thrombolytic Device
Arrow-Trerotola over-the-wire 7FR PTD kits are being recalled because the orange inner lumen of the catheter ' s tip may separate from the basket causing injury.News Alerts (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - December 6, 2021 Category: Cardiology Tags: Cardiology News Alert Source Type: news
Acute heart failure due to aluminum phosphide poisoning - Petrovic M, Otero D, Leigh A, Singh V.
We present a case of severe reversible cardiomyopathy and left ventricular apical thrombus in a patient who worked as an exterminator and had ALP poisoning.
... (Source: SafetyLit)
Source: SafetyLit - November 29, 2021 Category: International Medicine & Public Health Tags: Poisoning Source Type: news
Recurrent VTE More Common Than Thought With Isolated Subsegmental Pulmonary Embolism Recurrent VTE More Common Than Thought With Isolated Subsegmental Pulmonary Embolism
Low-risk patients with isolated subsegmental pulmonary embolism have a higher-than-expected rate of recurrent venous thromboembolism, a new study suggests.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - November 23, 2021 Category: Intensive Care Tags: Internal Medicine News Source Type: news
HEP-COVID Clinical Trial Results on the Prevention of Blood Clots HEP-COVID Clinical Trial Results on the Prevention of Blood Clots
WebMD ' s Chief Medical Officer, John Whyte, MD, speaks with Alex Spyropoulos, MD, a thrombosis expert, on his recent HEP-COVID randomized clinical trial involving COVID-19 patients, the blood thinner heparin, and reducing the risk of major blood clots.WebMD (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - November 17, 2021 Category: Infectious Diseases Tags: Infectious Diseases Expert Interview Source Type: news
Late-Breaking Phase 2 Data for Investigational Oral Factor XIa Inhibitor Milvexian Suggest Favorable Antithrombotic Profile Across a Wide Range of Doses
This study establishes proof-of-principle for milvexian as a differentiated antithrombotic agent,” said Jeffrey Weitz, M.D., Professor of Medicine & Biochemistry and Biomedical Sciences at McMaster University and Executive Director of the Thrombosis and Atherosclerosis Research Institute.[i] “Furthermore, the consistently low rates of bleeding across a 16-fold range of milvexian doses suggest that it has a wide therapeutic window, which opens the opportunity to explore milvexian across a broad range of patients including those for whom factor Xa inhibitors are underutilized or not indicated.” The trial met both o...
Source: Johnson and Johnson - November 15, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Deep vein thrombosis symptoms: Six early stage signs in your leg
DEEP VEIN THROMBOSIS is a blood clot in a vein that can be deadly, and it impacts as many as one in every 1,000 Brits every single year. Here are the six early-stage signs in your leg. (Source: Daily Express - Health)
Source: Daily Express - Health - November 15, 2021 Category: Consumer Health News Source Type: news
Newspath March 2014 - Hypercoagulablity Workup: Antithrombin Deficiency
Hypercoagulability is the main pathologic function needed to form a venous thrombosis (VT), a common cause of morbidity and mortality in many clinical settings. (Source: NewsPath - Pathology News for the Medical Community)
Source: NewsPath - Pathology News for the Medical Community - November 11, 2021 Category: Pathology Source Type: news
Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Guideline: Managing Coagulation Disorders in Cirrhosis Guideline: Managing Coagulation Disorders in Cirrhosis
A clinical update from the American Gastroenterological Association focuses on bleeding and thrombosis-related questions in patients with cirrhosis.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - November 5, 2021 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
VTE Can Occur in Moderate COVID-19 VTE Can Occur in Moderate COVID-19
A European study has found an elevated risk of venous thromboembolism in COVID-19 patients who were not critically ill.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - November 2, 2021 Category: Intensive Care Tags: Infectious Diseases News Source Type: news
Blood clot: Three signs in your leg of deep vein thrombosis - ‘contact your doctor’
BLOOD clots form to try and repair damage to a blood vessel. They are important to spot, as blood clots can cause deep vein thrombosis . This can be dangerous and you will need quick medical attention. (Source: Daily Express - Health)
Source: Daily Express - Health - October 31, 2021 Category: Consumer Health News Source Type: news
Antithrombotic Therapy Not Warranted in COVID-19 Outpatients Antithrombotic Therapy Not Warranted in COVID-19 Outpatients
In stable patients with COVID-19, use of aspirin or apixaban did not reduce the rate of the composite of all-cause mortality, thromboembolism, MI, stroke, or hospitalization in the ACTIV-4B trial.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 20, 2021 Category: Cardiology Tags: Cardiology News Source Type: news
Therapeutic - Dose LMWH Cuts Thromboembolism, Deaths in COVID - 19
Reduction in venous thromboembolism, arterial thromboembolism, and deaths seen in high - risk patients in non - ICU, but not ICU, settings (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - October 15, 2021 Category: Respiratory Medicine Tags: Infections, Internal Medicine, Critical Care, Nursing, Oncology, Pharmacy, Pulmonology, Journal, Source Type: news
